. Sudden death in asthma: discussion paper! M J Cushley MB MRCP A E Tattersfield MD FRCP Faculty of Medicine, University of Southampton Southampton General Hospital, Southampton S09 4XY Acute severe asthma is correctly regarded as a potentially lethal condition. This has not always been the case: from Trousseau's 'n'est pas fatale' to early this century, it was standard teaching that asthma was never the cause of death (Osler 190I) .
In the United Kingdom approximately 1500 people die each year from asthma, and onethird of these are under the age of 55 (British Medical Journal 1979) . Apart from the transient increase in mortality in the 1960s, the fatality rate has remained remarkably constant over the past 30 years, taking into account the minor changes which have occurred in the classification of asthma deaths. This is despite the introduction of oral and inhaled corticosteroids, selective beta-2 adrenoceptor agonists, sodium cromoglycate and slowrelease theophylline drugs. The failure to reduce mortality does not appear to be due to increased prevalence or severity of the asthma, though these cannot be entirely excluded.
How can we explain our failure to reduce mortality? A series of reports on deaths from asthma, commencing in 1953 and continuing to the present, have come to the same conclusions. There is a failure of patients and doctors to appreciate the severity of attacks of asthma and to summon appropriate help. Objective assessment of airflow obstruction is usually non-existent and treatment is delayed and inadequate (Macdonald et 01. 1976a , Ormerod & Stableforth 1980 . British Thoracic Association 1982 . The situation was summarized by Seaton (1978) : 'in almost no other field is the gap between diagnostic and therapeutic knowledge and its general application so great'.
Between 60 and 80% of patients dying from acute asthma die at home. For patients who reach hospital, the mortality rate can be well under I % in respiratory units; the results in general wards are less satisfactory (Hetzel et 01. 1977 , Crompton & Grant 1975 , Davis et al. 1980 . What potentially correctable factors contribute to this depressingly stable mortality? To answer this we need to know the natural history of the fatal attack and this is where problems arise.
Some studies have emphasized the sudden onset of most fatal attacks: 61% of deaths occurred within 8 hours of onset in a study of .deaths outside hospital from Cardiff (Macdonald et al. 1976b) , and 70 and 66% within 24 hours of onset in two further studies (Speizer et al. I968b, Ormerod & Stableforth 1980) . Others. however, suggest that a background of deteriorating function over days or weeks has preceded a severe or fatal episode (Macdonald et al. 1976a , Bellamy & Collins 1979 , Davis et 01. 1980 . How much deterioration has occurred prior to the fatal attack is largely unknown because theevidence is historical and objective measurements are invariably lacking. This was illustrated by a patient of ours who attended a non-urgent clinic appointment claiming to be reasonably well and, although unable to play games, she was attending school and working for '0' levels. When examined she had a quiet chest, central cyanosis and an FEV 1 of 0.15 Iitres. With any further deterioration she could well have died and. since she was attending school. a retrospective analysis would probably have called this a sudden death.
In practice there appear to be at least three patterns of severe or fatal attack. Probably most patients develop the fatal episode after days or weeks of deteriorating control. A substantial minority develop attacks within 24 hours, whilst a few patients deteriorate I Accepted 8 March 1983 o141-Q768/83/080662-Q5/$01.00/0 (0 1983 The Royal Society of Medicine rapidly over minutes (Arnold et 01. 1982) . Whether the pattern of deterioration in patients who die is different from the pattern in those who survive is not known.
Several surveys suggest that the major preventable factors contributing to death from asthma are inadequate assessment by patients, general practitioners and hospital doctors. and inadequate treatment.
Inadequate assessment

By patients
Failure by patients and relatives to appreciate the severity of an attack of asthma was considered to have contributed to 67 of 90 deaths in the recent survey of the British Thoracic Association (1982) . This could be due to a lack of perception of the severity of asthma or to a failure to act appropriately when deterioration is recognized. The relative importance of these two factors is difficult to ascertain without more knowledge of the pattern of deterioration in the fatal attack. Undoubtedly, the ability of patients to detect the . presence of airways obstruction varies considerably. When asthma was induced by methacholine, 15% of patients remained asymptomatic when marked airflow obstruction developed (Rubinfield & Pain 1976). Perception of breathlessness appears to be less in patients with chronic airflow obstruction and those with more marked hyperreactivity to histamine (Burdon et al. 1982) . Patients can be trained to recognize a worsening of their disease using a simple grading system (Davis et 01. 1980), and must be taught that an increase in bronchodilator aerosol requirements or failure of conventional treatment to relieve an attack is an indication to seek assistance urgently. Patients identified as having poor perception of the severity of their asthma should be given a home peak flow monitor, such as the mini-Wright peak flow meter. Asthma is, in many respects, like diabetes. and patients should be encouraged to increase home monitoring and responsibility for managing their disease. For the patient known to deteriorate rapidly, the facility for urgent selfadmission should be available. An emergency asthma self-admission service was pioneered in Edinburgh and has been in use there successfully since 1968 (Crompton et 01. 1979) .
In general practice Studies of asthma deaths indicate that general practiuoners often fail to appreciate the severity of attacks of asthma. Only 2 of II patients in one study (Ormerod & Stableforth 1980 ) and 12 of 21 in another (Macdonald et 01. 1976b) were referred to hospital when seen during their fatal attack. None of the patients remaining at home had an objective measurement of pulmonary function. Doctors should recognize severe asthma initially from clinical examination, including assessment of activity and speech. Heart rate is an excellent guide to the severity of asthma, with rates above 130 beats/min being associated with a high risk of major complications (Cooke et al. 1979) . Pulsus paradox us is common with severe airflow obstruction (Knowles & Clark 1973) , whilst a quiet chest and cyanosis are grave prognostic features. Clinical assessment should always be supplemented with an objective measurement of airflow obstruction, peak expiratory flow rate (PEF) or FEV I' These measurements are no more difficult or time-consuming than the measurement of blood pressure, and should, like bloed pressure, be considered as part of the clinical examination.
In hospital
Patients admitted to a respiratory unit with severe asthma have a full assessment on admission, and regular monitoring of PEF or FEV r-and often arterial blood gases. These patients rarely die. Patients dying in non-specialized units have usually not had pulmonary function measured on admission and virtually never thereafter (Macdonald et 01. 1976a , Ormerod & Stableforth 1980 . Respiratory crises are more likely to occur in patients with widely fluctuating peak flow values and a characteristic dip in the early morning (Hetzel et al. 1977) , the time when deaths on general medical wards tend to occur (Cochrane & Clark 1975) . Regular peak flow measurements allow patients with fluctuating values to be identified so that treatment can be supervised more closely. Arterial blood gas analysis . should be performed on all patients with severe asthma. The presence of hypoxaemia with hypercapnia rather than hypocapnia will identify patients likely to require assisted ventilation.
Inadequate treatment
Inadequate assessment in patients who die from asthma is often compounded by inadequate and inappropriate treatment. There are inevitably some differences of opinion about the optimum way to treat severe or deteriorating asthma, but broad guidelines would be agreed by most chest physicians. Gradual deterioration in asthma requires an increase in treatment, e.g. an increased dose of inhaled beta-agonist, the addition of an inhaled steroid or a course of oral steroids. Care is needed to ensure that the optimum dose of inhaled drug is taken and that the inhaler is used correctly. The place of methylxanthines is more controversial in view of their low therapeutic index and the wide interpatient variation in metabolism.
In patients with severe acute asthma, most physicians advocate high-dose parenteral or oral steroids in combination with beta-2 agonists, usually given by nebulizer. Oxygen is . normally given in high concentrations unless hypercapnia is present. Intravenous fluid will correct any dehydration, might assist in loosening secretions and provides vascular access if required. The routine administration of antibiotics does not influence the rate of recovery (Graham et al. 1982) . Some aspects of treatment are more controversial: whether betaagonists should be given by nebulizer or intravenously, the use of steroids in acute severe asthma, and the place of intravenous aminophylline. The nebulized route would appear to be the best route for administering beta-agonists initially, since high-dose nebulized betaagonists usually cause the same amount of bronchodilatation as intravenous beta-agonists with less tachycardia (Lawford et al. 1978 . Although steroids have been used for severe asthma since 1953, it has recently been suggested that they may not be necessary for acute episodes in patients not taking steroids regularly. This was based on an analysis of the rate of recovery of patients treated in a non-randomized manner with and without steroids (Luksza 1982) . The study has been criticized on several points (Grant 1982) , and the findings are contrary to a randomized study where steroids increased the rate of recovery (Fanta et al. 1982h) . Until the results of further studies are available, we believe that all patients with severe asthma should be given parenteral or oral steroids in high doses. Intravenous aminophylline is still standard treatment for acute asthma, though it is not clear how much this adds to high-dose nebulized beta-agonists (Fanta et al. I982a) . A dose adjustment is necessary for patients receiving regular theophylline treatment.
Patients who die from asthma have usually been given grossly inadequate or inappropriate treatment when compared to that given to patients in respiratory units with a low mortality. A study from Birmingham (Ormerod & Stableforth 1980) found that sedation had been given to 5 of the 15 patients who died in hospital. No patient received nebulized or intravenous beta-agonists during the first 24 hours. Twelve patients were given corticosteroids on admission, though the dose was often less than 10 mg oral prednisone. The situation was equally depressing for the 38 patients dying at home. None of the patients who visited their general practitioner in the two weeks prior to death had any significant alteration in treatment. Of the II patients seen during the final attack, treatment was unchanged in 3 and consisted of the addition of an antibiotic or bronchodilator aerosol only in 5. Steroids were increased to 20 mg in 3 patients only.
Are any deaths related to treatment? Although all studies have highlighted the importance of inadequate assessment and delayed and inappropriate treatment, it is also important to consider whether deaths might occur as a result of treatment. The rise in mortality from asthma in certain countries between 1961 and 1966 was especially marked in the younger age groups~an 8-fold increase in 10-14 year olds in Britain (Speizer et al. 1968a) . The increase coincided with the widespread use of isoprenaline metered-dose inhalers. The publicity following the suggestion that the two may be causally related led to a withdrawal of over-the-counter sales of isoprenaline inhalers in 1968. The increased mortality reached its peak in late 1966 and had returned to 'normal' by 1969 (Inman & Adelstein 1969 , the prescription of isoprenaline inhalers declining in parallel, though to a lesser extent. The countries spared this epidemic were mainly the countries not licensing the high-dose isoforte inhaler (Stolley 1972) . Arguments continue about whether the increased mortality was related to isoprenaline inhalers, and if so whether it was due to a direct effect of isoprenaline or to a false sense of security induced by the inhaler. Over-use or abuse of inhalers almost invariably reflects the need for further treatment. Delay in treatment and under-use of corticosteroids were important factors then, as now, though that alone does not explain why mortality should rise so suddenly in the 1960s.
In New Zealand, the 1960s' epidemic occurred a little later than in the UK and the mortality rate never returned to pre-1960s' levels. A second rise in asthma deaths has now been reported, starting in 1976 and currently causing a higher mortality than that seen in the 1960s and a mortality in young people more than four times greater than that in Britain (Jackson et al. 1982) . Although failure to instigate or increase corticosteroids is again apparent, the possible toxicity of treatment regimens has also been raised and in particular the combination of high-dose beta-agonists and theophylline on a regular basis (Wilson et al. 1981) . Animal studies have shown a greater incidence of arrythmias and death when the two drugs are combined (FDA Drug Bulletin 1981), but there is as yet no direct evidence of a causal relationship in patients. It is, however, very difficult to obtain this information in clinical practice since cardiac rhythm is rarely recorded at the time of death. The finding of widespread mucus plugging at autopsy would be expected in any patient with moderately severe asthma and does not exclude a drug-induced arrhythmia as the final coup de grace. Serious arrhythmias are obviously uncommon, but an incidence of one per 1000 acute episodes of asthma would be important, although very difficult to detect. It is impossible at present to know whether this is occurring in practice, though the combination of animal studies and the circumstantial evidence in the asthma epidemics suggest that drug-induced deaths might be contributing to the additional deaths during epidemics. All the evidence suggests that inadequate assessment and treatment are a much more important cause of non-epidemic asthma deaths.
What can be done to reduce deaths from asthma? Patients must, be taught to recognize deterioration in their asthma and to seek help when their usual medication fails. Patients identified as having poor perception of the severity of attacks should be given a peak flow meter to use at home. High-risk patients need close supervision and instructions for rapid admission when necessary. General practitioners must supplement clinical assessment with objective measurements of airflow obstruction. In hospital, objective measurements must be monitored regularly. Treatment should be started promptly and in our present state of knowledge should include oxygen, high-dose betaagonist therapy and corticosteroid therapy. Aminophylline may be used, though the dose must take account of whether the patient is on regular theophylline treatment.
